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Abstract: Chronic pain is a global health concern. This special issue on matters related to chronic
pain aims to draw on research and scholarly discourse from an eclectic mix of areas and perspectives.
The purpose of this non-systematic topical review is to précis an assortment of contemporary topics
related to chronic pain and its management to nurture debate about research, practice and health
care policy. The review discusses the phenomenon of pain, the struggle that patients have trying to
legitimize their pain to others, the utility of the acute–chronic dichotomy, and the burden of chronic
pain on society. The review describes the introduction of chronic primary pain in the World Health
Organization’s International Classification of Disease, 11th Revision and discusses the importance
of biopsychosocial approaches to manage pain, the consequences of overprescribing and shifts in
service delivery in primary care settings. The second half of the review explores pain perception as a
multisensory perceptual inference discussing how contexts, predictions and expectations contribute
to the malleability of somatosensations including pain, and how this knowledge can inform the
development of therapies and strategies to alleviate pain. Finally, the review explores chronic pain
through an evolutionary lens by comparing modern urban lifestyles with genetic heritage that
encodes physiology adapted to live in the Paleolithic era. I speculate that modern urban lifestyles
may be painogenic in nature, worsening chronic pain in individuals and burdening society at the
population level.
Keywords: chronic pain; analgesia; pain perception; sensory illusions; embodied pain; painogenic
environment; evolutionary mismatch hypothesis
1. Introduction
Chronic pain is a global health concern with evidence that patients are receiving inadequate
care, due in part to deficits in knowledge and skills of health care professionals [1,2]. Chronic pain
is a biopsychosocial phenomenon, yet pain education for health professionals continues to focus
on biomedical aspects of pain [3]. The purpose of this topical review is to précis an assortment of
contemporary issues related to chronic pain and its management to reveal the landscape of current
knowledge and thinking in the field. My intention is to bring certain issues to light through commentary
rather than comprehensive in-depth objective appraisal of research literature. The review is narrative
in style and I have based the direction and content of the review on what I find interesting and
controversial. I have attempted to integrate knowledge from a variety of disciplines including
philosophy, phenomenology, epidemiology, biomedicine, psychology, evolutionary biology and health
promotion. My approach is ambitious. Arguments are anthropomorphic in nature and cannot
be generalized to non-human species. I appreciate that the non-systematic approach to review is
vulnerable to selection and evaluation biases and opinion-oriented arguments, so I direct readers to
key references for comprehensive coverage of topics of further interest. I hope that some of the issues
discussed in the review prompts scholarly debate about future directions for research, practice and
health care policy.
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2. The Paradox of Pain
“To live in pain is not only to suffer aversive sensations but to be caught in a web of paradoxes”
Leder [4], p. 2.
2.1. Defining Pain
Historically, clinicians viewed pain as a secondary symptom of injury and disease and focused
treatment on removing the precipitating (primary) cause. Relief of pain was of secondary concern.
Nowadays the importance of alleviating pain is widely accepted. The International Association for the
Study of Pain (IASP) defines pain as: ‘An unpleasant sensory and emotional experience associated with actual
or potential tissue damage, or described in terms of such damage.’ [5]. The association between tissue damage
and pain is at the core of the definition, although the clause ‘ . . . or described in terms of such damage’
avoids always binding pain to the stimulus (i.e., potential or actual tissue damage). This is because pain
is a psychological state produced by the brain in response to a multitude of biopsychosocial inputs of
which activity in nociceptive (noxious detecting) pathways is but one. Often, scientists and clinicians
view pain as a technical problem solvable by biomedical interventions (e.g., drugs and surgery) that
target physiology, pharmacology, biochemistry, and molecular biology of the nociceptive system. This
approach has proven successful at advancing our understanding of the pathophysiology of pain and
identifying novel biomedical targets to alleviate pain. The focus on a biomedical approach has been at
the expense of the contribution of psychosocial and environmental factors in the lived experience of
pain. This may be one reason why management of chronic pain remains a challenge and the burden of
chronic pain on society continues to rise. Pain is complex.
2.2. The Lived Experience of Pain
The lived experience of pain is a perplexing mix of sensory, emotional and cognitive phenomenon
that fluctuate in and out of conscious awareness. The unpleasant nature of pain demands attention,
explanation and action to resolve actual or potential damage of the body. An assortment of
biopsychosocial and environmental factors influence the appearance, severity, character, and time
course of pain, although often pain is unpredictable. Pain may occur in response to noxious stimuli,
innocuous stimuli or in the absence of any apparent stimuli. From a phenomenological perspective
people report their experience of pain to fluctuate in the present and the past and the future; to be
localized and radiating everywhere; to be productive and destructive of value and meaning; and to be
never changing and ever-changing [4]. Often pain is amorphous.
2.3. Why Do We Communicate Pain?
Expression of pain is at the core of human group dynamics, serving to inform other individuals
that you are injured or ill. In modern society expressing pain has the potential to generate empathy in
others to motivate them to offer aid. Individuals evaluate a person’s expression of pain to determine the
extent of their disability and whether the person can fulfill their responsibilities. It seems plausible that
expression of pain was beneficial for our human ancestors living as hunter-gatherers in the Paleolithic
era [6]. Hunter-gatherer groups need to keep moving to search for food and avoid predation. Providing
assistance or care to group members who were injured or ill could be detrimental to a group’s ability
to acquire sufficient food or remain safe. Thus, the ability to legitimize pain to others would have been
important when trying to persuade others to provide care and assistance. Interestingly, individuals
could use this to their advantage by claiming to be in pain when in fact they were not, to avoid
dangerous tasks such as hunting trips. Legitimizing pain to others is particularly challenging in the
absence of visible cues of injury or illness because other group members may believe that the person
is expressing pain to seek an unfair advantage. It seems plausible that evolution has hardwired the
nervous system to exaggerate expression of pain (to be believed) and paradoxically hardwired the
nervous system to be skeptical about the existence of pain in others (to prevent being duped). This
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paradox plays out in the adversary struggle that chronic pain patients experience when trying to
legitimise their pain in the health care system [7–10].
3. The Struggle to Legitimize Pain
“To have pain is to have certainty; to hear about pain is to have doubt”
Scarry [11], p. 13.
3.1. Disproving Pain
Communicating the complex, dynamic, and multidimensional nature of pain experience is a
challenge. The amorphous character of pain does not sit comfortably with the objective nature of
medical practice and evidence suggests that chronic pain patients have difficulties convincing health
care professionals of the existence of pain [7,9,10]. Pain is a perceptual experience that is personal to
the individual and by definition unobservable by another person. The subjective nature of pain makes
it is impossible to prove or disprove a person’s pain and therefore it is not possible to distinguish a
person’s report of pain experience from that of tissue damage. A person’s report of pain should be
accepted if their sensory and emotional experience of pain is expressed in the same ways as that caused
by tissue damage. This was recognised in 1968 by McCaffery who defined pain as ‘ . . . whatever the
experiencing person says it is, existing whenever the experiencing person says it does’ [12]. Hence, conveying
pain experience depends on an ability to use language and/or behavioral action to communicate the
internal state of one’s body. It also depends on an ability to persuade others of the existence of pain in
oneself. Likewise, the observer needs to be receptive to what is being communicated, including being
able to interpret the meaning and importance of both verbal and behavioral information. This can
be challenging for individuals with limited verbal expression such as infants or with compromised
cognitive ability such as individuals with dementia. A recent systematic review of pain management
for community-dwelling people with dementia found that informal caregivers were more likely to
report pain on behalf of the person with dementia and pain-focused behavioral observation assessment
was infrequently used by practitioners [13]. Multimodal assessment of pain that includes self-reported
and non-self-reported measures have been developed to capture the complexity of pain experience [14],
although it is important to note that behavioral signs, effort testing, self-reported questionnaires,
or symptom validity tests have been shown to be unable to identify malingering [15].
3.2. The Tenuous Link between Pain and Pathology
Skepticism about the legitimacy of another person’s pain is at its height when there is an absence
of evidence of injury or disease [16]. For example, pain may be driven by central sensitization
and/or abnormal functioning of the nociceptive system, and/or altered higher level processing such
as fear-avoidance behavior. Unlike many illnesses, pain is not visible or measurable using objective
means and clinicians have to rely on patients’ self-report, coupled with observation. Subjective
and objective assessment, including the patient’s report of symptoms, examinations of functional
capacity, and diagnostic tests, contribute to pain diagnoses. When legitimizing pain and constructing
logical explanations for pain, patients and non-pain specialist practitioners tend to give credence
to positive diagnostic tests related to tissue pathology, at the expense of alterations in physiological
processing associated with pain se (e.g., central sensitisation). Diagnostic imaging techniques are
critical for detecting sinister pathology in patients presenting with pain. However, tissue pathology
may be present in the absence of pain [17] so paradoxically, evidence of tissue pathology may be
counterproductive when searching for causes of pain in some circumstances Thus, in some instances
the relationship between pain, injury and disease may be tenuous.
Pain may occur in the absence of injury. A clinical anecdote by Fisher et al. [18] described the
case of a builder who presented to accident and emergency complaining of severely disabling pain
due to a 15-cm nail that had penetrated his boot. The builder needed strong analgesia and sedation
before physicians were able to remove the nail from the boot. On removing the boot from the foot, they
Medicina 2019, 55, 182 4 of 19
discovered that the nail had lodged between the toes without causing tissue damage! Pain may occur
in the presence of minor injuries. A sliver of metal embedded in the skin of a finger is a good example.
Paradoxically, serious injuries may be devoid of pain. Beecher et al.’s seminal paper reported that over
50% of soldiers with fresh combat wounds reported mild or no pain [19]. Evidence suggests that high
proportions of individuals without pain have pathological changes associated with aging [17]. Clinical
care pathways for some chronic pain conditions do not recommend diagnostic imaging in the absence
of red flags (e.g., non-specific low back pain [20]). Pathology may not always be driving pain.
3.3. Pain is Not a Unitary Phenomenon
Clearly, the dynamic, multidimensional, and amorphous nature of pain is challenging to capture
with any degree of specificity and precision. Commonly, pain is reduced to a unitary phenomenon
measured by numerical intensity rating scales. This approach is convenient and psychometric research
evidence suggests that data gathered from scales is valid and reliable [21–23]. However, rating scales
do not measure pain objectively and can give a false impression of the level of measurement precision
(e.g., 1 mm on 100-mm visual analogue scale). Scales presume linearity of subjective report between
scale ends and use anchors that are nebulous (e.g., ‘The worst-ever pain’ or ‘The worst pain imaginable’).
Patients have been known to extend scale ends to incorporate incidents that have provoked pain
beyond the worst they had previously thought imaginable [24]. The measurement of pain in this
way is not only imprecise but is also fails to capture the complex and subjective nature of pain.
To overcome the restrictions associated with numeric scaling Wideman et al. [14] have offered a
multimodal assessment model of pain that describes quantitative aspects of pain such as self-reported
and non-self-reported measures, and importantly, qualitative aspects of pain such as the words and
behaviors of the patient’s narrative. This practical framework assists the integration of the subjectivity
of pain within assessment. The inclusion of, and importance paid to, the narrative report captures more
fully an individual’s pain experience helping to legitimize pain for both patient and practitioner. This
promotes a compassion-based consultation and provides much information that enriches assessment
of the underlying processes contributing to pain.
4. Chronic Pain
4.1. Reassessing the Acute–Chronic Dichotomy?
Traditionally, service delivery and clinical practice views pain through an acute or chronic lens.
Acute pain is pain persisting less than twelve weeks. Chronic pain is often secondary to disease or
traumatic injury and initially considered a symptom. Chronic pain is pain that persists or recurs
for twelve weeks or more, or beyond the expected time for healing. Recently, Loser argued that the
acute–chronic dichotomy is so entrenched in pain parlance that it has escaped critical scrutiny [25].
There are no temporal correlates of physiological processes associated with pain based on time points
used to distinguish acute and chronic. Loser argues that we should describe pain syndromes based
on physiological mechanisms, including peripheral or centrally generated perspectives as originally
discussed by John Bonica in the 1950s.
From an evolutionary perspective, hypersensitivity of the nervous system serves to assist the
healing process by amplifying and prolonging pain. This discourages use of, and contact with, injured
tissue. Peripheral sensitization is driven by the release and production of biochemical mediators at
the site of tissue damage that lower the threshold of activation of transducer ion channel receptors
expressed in nociceptor terminals. Sometimes the adaptive function of peripheral sensitization is
lost as is the case for some autoimmune diseases such as rheumatoid arthritis that generates ongoing
inflammation, peripheral sensitization and pain hypersensitivity even though healing does not occur.
Central sensitization is centrally mediated amplification of pain irrespective of mechanism or
location. Central sensitization is triggered by noxious (excitatory) input arising from direct activation of
nociceptors (nociceptive) or from damaged or dysfunctional neuronal fibers (neuropathic). Nerve injury
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can reduce segmental and/or extrasegmental inhibitory influences on central nociceptive transmission
(i.e., disinhibition) through a loss of interneurons, loss of descending pathways, altered connectivity
and microglial activation. These mechanisms lower the threshold of excitation of central nociceptive
transmission neurons, amplifying their output to noxious and non-noxious stimuli [26]. The molecular
mechanisms are multifactorial and complex with NMDA (N-Methyl D-Aspartate) receptors having
a critical role, in a process similar to long-term potentiation associated with memory formation.
The receptive fields of central nociceptive transmission neurons also expand so that they become
responsive to stimuli applied to areas of tissue that do not normally activate them. Thus, central
sensitization increases the area of pain hypersensitivity across body parts.
Central sensitization manifests primary and secondary hyperalgesia and allodynia and sometimes
pain presents spontaneously in the absence of nociceptive stimuli. Patients may present with
widespread pain in multiple body regions and pain arising after mundane activities such as walking
or cooking. Yunus coined the term central sensitivity syndrome to describe pain-related conditions
without obvious tissue pathology, that have similar comorbid symptoms (e.g., poor sleep hygiene,
fatigue, and slowness of cognition) and include fibromyalgia and irritable bowel syndrome [27].
4.2. Nociplastic Pain: A New Mechanistic Descriptor?
Presently, mechanistic categories of pain are; nociceptive pain, resulting from activation of
nociceptors by a noxious stimulus that is damaging or threatens damage to healthy tissues (other than
neural structures); and neuropathic pain resulting from a lesion or disease of the somatosensory nervous
system. Recently, Kosek et al. [28] have proposed consideration of a third mechanistic descriptor,
nociplastic pain (other candidate terms offered were algopathic or nocipathic pain), to describe pain
arising from altered central nociceptive processing in the absence of tissue damage. Kosek et al.
argue that inclusion of nociplastic pain, or some other equivalent, in the vocabulary of pain would
raise awareness that pain may present without detectable tissue damage and promote screening for
signs of nociceptive dysfunction to improve diagnosis and treatment. Nociceptive and neuropathic
mechanisms that contribute to pain are proven and can be detected using various techniques including
biochemical investigations, radiology, nerve conduction tests and imaging of the nervous system.
It is important to recognize that the terms nociplastic, nociceptive and neuropathic are not diagnoses
or exclusive categorical labels but descriptors of concurrent potential mechanistic drivers of pain.
Nevertheless, the term nociplastic pain could help patients create explanatory models of their pain
experience to legitimize their pain to others.
4.3. The Burden of Chronic Pain
Most literature discusses pain from an acute–chronic dichotomy. Chronic pain affects between
15–30% of the general adult population [29–31], with severe, debilitating chronic pain affecting 10–15%
of adults [32]. Healthcare and socioeconomic costs of chronic pain is high and estimated to be 3–10%
of gross national domestic product in Europe [33]. In the United States annual costs related to health
care delivery and lower worker productivity due to chronic pain is estimated to be between $560 and
$635 billion dollars and greater than heart disease ($309 billion), cancer ($243 billion), and diabetes
($188 billion) [34].
People do not die directly of pain, and unlike functional impairment, pain is not visible. Pain is
often secondary to other medical conditions. Health care policies often focus on curing or slowing
progression of the primary disease as a means to improve functional outcome, and may neglect
pain management. For example, pain is underdiagnosed and inadequately managed in neurological
conditions [35,36], despite high prevalence (e.g., Parkinson’s disease (40–85% (range) [37]), multiple
sclerosis (55–70% (95% confidence intervals (CI)) [38]), motor neuron disease (19–85% (95% CI) [36])
and Alzheimer’s disease (38–75% (95% CI) [36]). There has been a long-standing debate whether
chronic pain should be considered a disease entity in its own right under certain circumstances [39].
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4.4. International Classification of Diseases: Chronic Primary Pain
The 11th edition of the World Health Organization’s International Classification of Diseases
(ICD-11) categorises chronic pain as secondary to other conditions: chronic cancer-related pain, chronic
neuropathic pain, chronic secondary visceral pain, chronic posttraumatic and postsurgical pain, chronic
secondary headache and orofacial pain, and chronic secondary musculoskeletal pain [40]. The ICD-11
recognises that in some circumstances, chronic pain may not be explained by the presence of another
condition and require special treatment and care in its own right. Thus, ICD-11 includes a category for
chronic primary pain to reflect in part that pain should be regarded as a pathologic entity in its own
right and characterized by a dysfunctional nervous system with persistent central sensitization (for
review of the history of this debate see Raffaeli, and Arnaudo [39]).
Chronic primary pain defies classical pathological based classification and is described as pain as
the primary complaint in one or more regions of the body and causing significant emotional distress
or functional disability. Specific examples include chronic widespread pain, fibromyalgia, irritable
bowel syndrome and non-specific chronic low back pain. Chronic primary pain draws attention to the
much broader spectrum of possible biological, psychological and social causes and consequences than
tissue damage or on going disease. The premise that pain is a biosychosocial phenomenon is widely
accepted but social components of pain are often absent from pain definitions. Recently, Williams and
Craig have called for the IASP to re-consider its definition of pain to highlight the contribution of social
elements in pain experience, as follows: ‘ . . . a distressing experience associated with actual or potential
tissue damage with sensory, emotional, cognitive, and social components’ [41] (p. 2420). This would draw
further attention to the need to deliver holistic models of care.
5. Desirable Models of Care
It is recommended that patients with chronic pain are managed using a biopsychosocial model
of care with pharmacological and non-pharmacological interventions tailored to the needs of the
individual [42]. Care plans should promote physical and psychological wellbeing through lifestyle
adjustments (e.g., in diet and physical activity), psychological interventions (e.g., cognitive behavioral
therapy), and non-pharmacological adjuncts such as manual therapies, transcutaneous electrical
nerve stimulation (TENS), thermal therapies, acupuncture, low level laser therapy, mirror therapy
and virtual reality. The World Health Organization promotes the use of multidisciplinary teams
working in partnership with patients to co-create explanations about pain and construct care plans that
empower individuals to be active participants in their treatment because it creates self-efficacy [42–44].
Traditionally, first line treatment for pain involves the use of analgesic and adjuvant drugs that
modulate nociceptive system processing, and the simplicity, convenience and partial success of this
approach has meant that it dominates service delivery in many parts of the world.
5.1. The Analgesic Ladder
The World Health Organization’s analgesic ladder, initially developed for cancer pain [45],
advocates a stepwise approach to prescribing starting with mild analgesics and increasing dosage
or switching to powerful analgesics if pain is not adequately managed. Paracetamol or nonsteroidal
anti-inflammatory drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), e.g., diclofenac and
ibuprofen) are prescribed for mild to moderate non-neuropathic pain, stepping up to weak opioids (e.g.,
codeine and dihydrocodeine) for moderate pain, and strong opioids (e.g., morphine and oxycodone)
for moderate to severe pain. Prescribers also use local anesthetics for mild pain (e.g., mouth ulcers),
and for moderate to severe pain (e.g., during and post-surgery). Adjuvants are drugs whose primary
use was not originally for relief of pain and are used to manage neuropathic pain (e.g., amitriptyline,
duloxetine, gabapentin or pregabalin) or muscle spasm (e.g., baclofen).
Analgesic drugs interact with nociceptive pathways to inhibit the onward transmission of
noxious information from the site of injury to the brain in order to alleviate pain. Non-steroidal
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anti-inflammatory drugs inhibit cyclooxygenase reducing the production of prostaglandins that
normally sensitize nociceptors; opioids prevent onward transmission of nociceptive transmission in
the central nervous system; and local anesthetics block sodium channels reducing transmission of
nerve impulses in nociceptive fibers. Analgesic and adjuvant medications are extremely valuable
for short-term management of pain and used cautiously in the long-term. The largest pan European
survey of chronic pain found that 64% of participants stated that medication did not adequately control
pain [2]. It may be difficult for some health care professionals to accept that long-term drug medication
may not be the best option and that the multidimension nature of pain means that response to drug
intervention is highly malleable. This malleability is demonstrated in research using open-hidden
paradigms. A review of experimental evidence by Benedetti [46] provided evidence that the efficacy
of analgesic drugs is modulated by cognitive and affective state. Administering a placebo (fake)
drug coupled with the suggestion that it is an analgesic drug increases analgesia and administering
an analgesic drug with the suggestion that it is a placebo (fake) drug reduces analgesic outcome.
The addition of open-label placebo treatment as an adjunct to treatment for chronic lower back pain
has been shown to be safe and effective at reducing pain raising interesting ethical debates about the
role of placebos in treatment [47].
5.2. Overprescribing
Concerns have been expressed about detrimental consequences to individuals and society of over
diagnosis and over prescribing for chronic long-term illnesses, including chronic pain [48,49]. Abuse
of prescription opioids is a major problem in some Western countries [50], although paradoxically,
restricted access to opioids impedes pain management in parts of Asia, Africa, and Middle East [51].
The use of prescription opioid medication in the United States has risen from 4.1% in 1999–2000 to
6.8% in 2013–2014, with long-term users rising from 45.1% of all opioid users in 1999–2000 to 79.4% in
2013–2014 [52]. Social, economic and environmental variables are as influential in the opioid epidemic
as health and biomedical factors. Recently, cross-sectional analyses of individual and county-level
demographic and economic factors have found that elevated mortality from opioid overdose due to
increased opioid prescribing was positively associated with direct marketing of opioid medication to
physicians [53], and that chronic opioid use was positively associated with presidential voting patterns
in USA counties [54]. Abuse of prescription opioids demonstrates the need for greater caution and
selectivity in prescribing of long-term opioid therapy. Ironically, as one drug loses favor others come
into view.
5.3. Novel Centrally Acting Drugs
There is a debate whether plant-based cannabis preparations could replace opioids [55]. There is
low-level evidence that cannabinoids alleviate neuropathic pain and insufficient evidence to recommend
their clinical use for other types of pain [56,57]. Presently, professional bodies recommend that
cannabinoids be considered in exceptional circumstances for neuropathic pain, chronic non-malignant
pain and cancer pain when patients are not responding to other treatment [58]. Centrally acting
psychedelic drugs such as lysergic acid diethylamide and psilocybin have also attracted interest for the
management of chronic pain [59]. Psychedelics act as agonists at 5-HT2A receptors and may modulate
pain through action in the rostral ventromedial medulla enhancing descending pain inhibitory pathway
activity [60]. Psychedelics influence metacognitive interpretation of pain including the resting state of
awareness mediated by the default mode network in the brain [61]. Pain interferes with activity in the
default mode network causing intrusive cognition and the breakdown of normal self [62]. Only a few
small studies without controls exist that suggest potential benefit of psychedelics for cluster headache
and malignant and neuropathic pain [59].
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6. Service Delivery in Primary Care
The value of analgesic medication is undisputed providing it is within a biopsychosocial model of
care. Adams and Turk [63] suggest that a biopsychosocial perspective, rather than a singular biomedical,
or psychological, or social perspective, is necessary to fully understand the lived experiences of people
with chronic central sensitivity pain syndrome. A comprehensive approach to assessment is optimal to
address physical, emotional, and social functioning and a palliative approach is optimal to manage
pain and distressing symptoms because there are no curative treatments. However, resource pressures
often hinder the delivery of a truly biopsychosocial model of care by multidisciplinary teams in primary
care settings.
6.1. Shared Appointments and First Points of Contact
Employing multidisciplinary teams of physicians, nurses, physiotherapists, psychologists,
dietitians and occupational therapists can be financially costly. Traditionally, the first point of
contact is the primary care (general) physician (GP) who conducts a short one-on-one ten-minute
consultation with the patient to assess, diagnose, agree appropriate treatment and discuss difficult
concepts. This consultation often feels rushed with GPs having similar consultations with different
patients over the course of a day. Shared appointments may be a more cost-effective model of service
delivery than one-to-one consultations and have been successful for the management of diabetes, and
obesity [64]. Shared appointments involve each patient consulting with the clinical team, with elements
of group education and discussion between patients, and peer support by learning from the experiences
of other patients. Patients impart information more readily in shared appointments and engagement
with patients with similar conditions provides motivation for health behavior change. There is
increasing use of shared medical appointments for persistent pain [64]. Moreover, physiotherapists
and nurses may be better suited than GPs as a first point of contact to diagnose and advise patients
with non-complex chronic pain [65].
6.2. Social Prescribing
Some countries have adopted programmes of social prescribing to provide patients in primary care
with sources of support within their community. Social prescribing enables healthcare professionals
to refer patients to non-medical personnel who work with the patient to co-design a nonclinical
social prescription to improve health and well-being [66]. Social prescriptions include access to
practical information and advice, community activity, and physical activities provided by voluntary
and community sectors. A systematic review of 15 evaluations of social prescribing schemes in UK
settings could not reliably judge effectiveness or value for money because evaluations had a paucity of
data and methodological limitations, although conclusions of individual evaluations were generally
positive [67]. Social prescribing schemes seem to be an ideal fit for the management of many chronic
pain conditions because social prescribing addresses psychological, social and environmental factors
affecting health and well-being associated with pain.
7. Pain Perception: Active Top-Down Processing?
Classically, a ‘bottom-up’ stimulus-organism-response model describes the physiological
processes involved in producing pain sensation. The model inadvertently implies that pain
is an inevitable consequence of activity in the nociceptive system driven by tissue damage.
This stimulus-organism-response model has been refined to incorporate changes in the sensitivity of the
nociceptive system and top-down processes that facilitate and inhibit nociceptive transmission [68,69].
Melzack suggested that the multidimensional experience of pain resulted from characteristic patterns
of nerve impulses (i.e., a neurosignature) produced within multiple widely distributed neural networks
in the brain that are genetically determined and modified by sensory experience (i.e., body-self
neuromatrix theory of pain) [70]. Melzack suggested that multiple factors influenced the output
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patterns of the body-self neuromatrix, of which noxious input was only one. This would explain why
pain sometimes arises and/or persists despite limited noxious input.
7.1. Maleability of Perceived Properties of the Body
Predictions and expectations are a core feature of the central nervous system processing enabling
the brain to generate perceptual experiences based on snippets of multisensory input. This ‘perceptual
inference’ is involved in the generation of the sense of ownership of body parts, and in the location of
sensory events, including pain, within the body. The perceptual qualities associated with the sense of
body ownership are malleable as demonstrated by somatosensory illusions.
The rubber hand illusion demonstrates how rapidly the brain can update assumptions about the
location of stimuli and ‘ownership’ of body parts. An individual watches a rubber hand stroked with
a brush whilst their real hand is stroked in synchrony but hidden out of view [71]. Within minutes,
the sensation of stroking feels as if it is arising from the rubber hand and the individual experiences a
sense that the rubber hand has become part of their body (i.e., the rubber hand has been embodied
and the real hand disembodied) [72]. Approaching a perceptually embodied rubber hand with a
threatening stimuli may elicit somatosensations in some individuals including pain, subjective anxiety
and skin conductance responses that are similar in magnitude to that experienced when a real hand is
threatened [73,74].
The marble hand illusion demonstrates how the brain can update assumptions of the material
qualities of the body. The illusion involves gently hitting the hand with a hammer and progressively
replacing the sound of hammer blow on skin with a hammer blow on marble. Within five minutes
the hand feels stiffer, heavier, harder, less sensitive and unnatural [75]. Protecting a virtual limb
with a virtual iron armor cover can reduce electrically evoked pain [76] and hearing a creaky door
when moving a stiff joint or back increases the need to protect the spine whereas hearing a gentle
whoosh reduces the need to protect [77]. In fact, perceptual stiffness in the back was found not to be a
representation of biomechanical properties of tissue but rather a perceptual inference error of stiffness,
in other words, “ . . . feeling stiff does not equate to being stiff in chronic low back pain” [77] [p2]. Thus,
the brain operates to reduce threat and preserve coherent behavior according to situational context and
these perceptual inferences can operate in both directions, i.e., pain or analgesia [78,79].
7.2. Multisensory Perceptual Inference as a Protector
Pain is never motivationally neutral. Pain is a potent driver of action in much the same way as thirst
drives drinking and hunger drives eating, because the cost of ignoring pain may result in tissue damage,
disrupted homeostasis and threat to life. Outcomes of behaviors that do not meet predictions (i.e.,
are unexpected with a large prediction error) have a major influence on future behavior. Unexpected
pain, such as a severe lancinating shooting pain during an innocuous movement, is likely to have a
disproportionately large effect on the expected intensity of future encounters with the same stimuli.
Unexpected pain is likely to amplify multisensory perceptual inference serving to protect the integrity
of tissue by creating, for example, fear-avoidance of movement (i.e., the motivational-decision model
of pain [80]). Individuals experiencing pain over-estimate the distance and the effort needed to walk to
a target [81] and perceive targets to be further away [82] (i.e., economy of action hypothesis), although
potential scaling of spatial perceptions during pain have not been consistently demonstrated [83].
Actions that fail to restore coherence of behavior may also contribute to perceptual dysfunctions
accompanying pain. Examples include phantom limbs stuck in one position [84], and painful
limbs feeling excessively large in complex regional pain syndrome [85,86], or excessively small in
osteoarthritis [87]. Contemporary models of pain perception are attempting to integrate sensory,
affective, cognitive, social, and bodily cues interpreted within social, environmental and evolutionary
contexts, including previous experiences, from the perspective of embodied cognition.
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7.3. The Theory of Embodied Pain
The embodied theory of pain designates pain as arising from situations that infer bodily threat to
drive behaviors to reduce the impact of the threat on the integrity of tissues (i.e., defensive) whilst
maintaining the integrity of rational behavior [88]. The embodied theory describes pain as a dynamic,
motor experience rather than a passive, sensory experience and blurs the distinction between perception
and action: “Pain is always about action.” ([88], p. 3). The embodied theory of pain places the body
and its ability to investigate the environment through a dynamic exchange of information between
nervous system and environment at the core of pain experience. Thus, the brain uses information
about previous encounters with pain and previous behaviors on pain to ‘flavour’ pain experience.
For example, individuals report thermal stimuli to be hotter and more painful when delivered in
synchrony with a red light (often associated with heat) compared with a blue light [89]. Appreciating
that the brain uses multisensory perceptual inference to predict likely consequences of undertaking
defensive behaviors offers opportunities for therapeutic interventions [88,90–93].
7.4. Multisensory Perceptual Inference to Alleviate Pain
Therapeutic opportunities can arise from manipulating the environment and context to reinstate
coherence of behavior and normalize perception. Mirrors, lenses, and virtual reality have been used
to alleviate pain and improve function through visual distraction, ‘normalizing’ the appearance of
dysmorphic painful body parts, reducing threat associated with moving painful body parts, and
aligning ownership and agency of body parts through visual, proprioceptive, and tactile congruency.
Therapeutic success is varied and research findings from systematic reviews of controlled clinical
studies are inconsistent due to a paucity of robust primary studies [94–97].
Advanced technologies that couple visual, auditory, and haptic (tactile) stimuli, such as vibration
in hand held game controllers and force feedback systems for medical and military training are being
adapted to manipulate the multisensory environment impinging on the body influencing embodied
and embedded perceptual experience. Immersive virtual reality technology using head-sets and
non-immersive virtual reality technology using computer screens can be used in combination with
motion tracking systems so that movements of an individual’s real limb can be used to control the
movement of a virtual limb. Pain may be modulated when individuals are immersed in different
virtual reality environments [98,99]. Virtual and augmented reality technologies providing enriched
practice environments tailored to individual needs are being used in recovery and rehabilitation after
brain damage or injury to facilitate motor learning and neural plasticity. Virtual reality offers several
opportunities for pain management including distraction from painful body parts, providing contexts
that reduce perceived threat, resizing of painful dysmorphic body parts, re-embodiment of alienated
and/or disowned painful body parts, and modulation of agency to facilitate movement of painful body
parts accompanied by fear-avoidance of movement.
Task-oriented virtual reality provides opportunities to reduce the sense of threat associated with
moving painful body parts accompanied by fear-avoidance of movement [100–103]. For example,
Ortiz-Catalan et al. [104] designed a virtual environment as a rehabilitation training aid for individuals
with amputated upper limbs. Surface electrodes were used to record muscle activation over the stump
of the residual limb whilst individuals tried to voluntarily control a virtual phantom limb that was
displayed in real-time on a computer screen. Motor volition was decoded using myoelectric pattern
recognition software whilst the patient matched random target postures or attempted to drive a virtual
car using the virtual limb. Improvements in phantom limb pain occurred after 12 training sessions that
was sustained for six months post-training.
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8. Social and Environmental Contexts
At the core of multisensory perceptual inference of pain is the social context in which an individual
lives, including previous experiences associated with pain. Thus, an individual’s pain experience is
embedded in environmental settings.
8.1. Lifestyle and Chronic Pain
Increasingly, modern human lifestyles are embedded in urban environments. Modern urban
lifestyles are associated with mortality and morbidity of noncommunicable ‘lifestyle’ diseases, such as
cardiovascular diseases (heart attacks and stroke), chronic respiratory diseases (chronic obstructed
pulmonary disease and asthma), diabetes and cancer [105]. Chronic pain is a secondary consequence
of many of these non-communicable diseases causing suffering, disability and a significant impact
on quality of life. The Global Burden of Disease Study 2013, found that chronic low back pain
had the highest number of years lived with disability [106]. Some lifestyle behaviours are risk
factors for non-communicable diseases including sedentary activity, unhealthy diet, anxiety and
depression, smoking, lack of sunshine, disrupted sleep, unemployment, living in adverse socioeconomic
circumstances, and previous history of abuse or violence [107–109]. The relationship between these
lifestyle factors and chronic pain is complex and unclear with causal processes likely to be acting in
both directions.
Built and food environments are known to promote obesity in populations and has been described
as obesogencity of urban environments [110]. The concept of an obesogenic environment has helped
to focus attention upstream on whole systems public health solutions including the design of urban
environments [111]. There are similarities between obesity and chronic pain [112]. Both conditions
disproportionately affect poorer people society; are associated with high economic and social costs;
are influenced by biopsychosocial factors including physical activity and diet; and are managed using
pharmacological, educational and behavioural interventions. This raises the possibility that modern
urban environments may be painogenic in nature [113].
8.2. Painogenicity of Modern Urban Living
Painogenicity is the sum of influences that the surroundings, opportunities or conditions of life
have on promoting persistent pain in individuals or populations [113]. Modern urban environments
generally consist of air polluted with toxic emissions and particulates, high population densities,
limited green open space and readily available processed foodstuffs. Consequently, there has been a
shift toward sedentary lifestyles and high calorie diets of over processed food with excess sucrose, salt,
fat and additives, both known to contribute to noncommunicable ‘lifestyle diseases’ (c.f. Sick City
Syndrome, Modern Urban Living Syndrome) [114]. The shift to modern urban living is more rapid than
physiological adaptation resulting in a potential evolutionary mismatch [114,115]. An evolutionary lens
has been used to explore the biological role of sensitization and hyperalgesia in chronic pain [78,116–118]
but little is written about the contribution of evolutionary mismatch to chronic pain [113].
8.3. Chronic Pain and Evolutionary Mismatch
Evolutionary mismatch may provide insights to potential painogencity of modern urban
environments. Our genetic heritage encodes physiology adapted for hominin ancestors that existed in
the Paleolithic era, circa 4–7 million years ago with clean air, exposure to microorganisms and lifestyles
consisting of walking, climbing, lifting, carrying and bending and diets of fresh vegetables, fruit and
raw meat (i.e., hunter-gatherer lifestyles). Paleolithic ancestors existed in calorie-limited environments
and were adapted to minimize energy expenditure wherever possible and maximise consumption of
fat, sugar and salt driven by cravings. Paleolithic ancestors existed in outdoor environments with direct
exposure to microorganisms and parasites through contact with soil, plants, and animals resulting in a
diversity of microorganisms thriving on the skin and within the gastrointestinal tract (i.e., the human
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microbiota) [119]. The symbiotic relationship between the human microbiota, acquired after birth,
and the immune system drives protective responses to pathogens and tolerance to innocuous antigens.
In contrast, modern urban dwellers exist in towns and cities and have lifestyles that are indoors
and involve consumption of over-processed foods, and prescription and recreational drugs. Modern
urban lifestyles are becoming increasingly sedentary with excessive amounts of time being physically
inactive leading to ‘disuse syndromes’ (e.g., ‘walking deficiency syndrome’, ‘hyper-sitting syndrome’)
and an increased risk of non-specific chronic musculoskeletal pain [120–122]. The shift to urban
living is associated with a decline nutritional diversity due to consumption of fewer vegetables, fruits,
antioxidants and omega-3 fatty acids and a rise in consumption of high calorie over-processed foods
creating diet-induced proinflammatory states [123]. The gastrointestinal microbiota–brain axis of
modern humans has been disrupted by the shift to indoor living with environmentally controlled
air, sanitation, processed foodstuffs, and the use of pharmaceuticals to eradicate infections and
parasites. Reduced exposure to microorganisms in childhood results in immune systems unable
to differentiate pathogens that confer benefit or harm and this may contribute to inappropriate
immune (allergic) responses to harmless allergens associated with a disrupted microbiota resulting
in inflammatory responses and peripheral and central sensitization of the nociceptive system [124].
Evidence suggests that abnormal immune responses may directly influence processes associated
with sensitization of the peripheral and central nociceptive system through atypical regulation and
output of the hypothalamic–pituitary–adrenal axis including downstream signaling that sensitizes
nociceptive afferents [125]. These processes may be contributory factors in visceral pain resulting
from inflammatory bowel disease, celiac disease, and metabolic syndrome [119] and idiopathic pain
disorders manifesting with persistent central sensitization such as fibromyalgia, chronic pelvic pain,
and migraine [125].
Current models of care for chronic pain, especially related to the musculoskeletal system,
promote lifestyle adjustment. In essence, they are attempting to rebalance this evolutionary mismatch.
Physical activity and diet is at the core of lifestyle adjustment (e.g., for non-specific chronic low
back pain [20]). Diet therapies that increase consumption of antioxidants and omega-3 fatty acids,
and reduce consumption of exocitoxic substances (e.g., monosodium glutamate, hydrolyzed protein,
protein isolates/concentrates, yeast extract, aspartame) and foodstuffs (e.g., bran, nuts, soybean,
and aged cheeses) may alleviate chronic pain [126–128]. Dietary interventions such as probiotics
and prebiotics may prove beneficial to alleviate visceral hypersensitivity associated with a disrupted
microbiota [119,129]. However, adherence to long-term lifestyle adjustment is poor and this may be
due to the social and environmental conditions in which patients live.
9. Upstream for Solutions
Clinical guidelines recommend that practitioners counsel people living with persistent pain to
undertake healthy lifestyles. Pain education about the nature of lifestyle adjustments is prominent in
pain discourse but incongruous social and environmental conditions may hinder long-term behaviour
change. Consideration of upstream solutions may help to reduce chronic pain at both individual and
population level.
9.1. Social Models of Health Promotion
People with chronic pain prioritize justice-related issues within the context of their personal
concerns and needs [130]. Low socioeconomic status, poor working conditions or unemployment,
unstable home life, low levels of education, and living in deprived environments are associated
with increased pain [108]. People with chronic pain believe that treatment of chronic pain is
unfair [131]. Interpretative phenomenological analyses demonstrate that chronic pain patients
from lower socioeconomic groups express concerns associated with unfair advantages of others,
whereas those from middle socioeconomic groups are concerned with a battle for quality of life, and
those from upper socioeconomic groups with the quality of care [130].
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Social models of health promotion have been used successfully to tackle social injustices detrimental
to health and wellbeing, such as poverty, provision of inexpensive foodstuffs that encourage healthy
diets, poor housing and lack of employment [132]. There is however, limited discourse about the use
of social models of health promotion within pain literature [133].
9.2. Evolutionary-Concordant Environments
There are also constraints of healthy living imposed by the nature of built environments. Often,
urban environments are not conducive to undertaking physical activity outdoors due to limited
greenspace, fear for personal safety, and air and noise pollution. Indoor activities may introduce
additional issues such as transportation to and from a gym, financial expense to use a gym, and chronic
overuse injuries such as strains and tendonitis from, for example, jogging on treadmills in restrictive
shoes [134]. The Evolutionary Determinants of Health program launched in 2014 provides a framework
for debate of evolutionary-concordant healthy cities and social regimes for urban societies, with green,
open spaces and clean air to encourage individuals to be physically active [135]. However, there needs
to be commitment on the part of policy makers to address social injustices and construct healthy urban
environments to enable patients and individuals to live healthy lifestyles.
10. Conclusions
Chronic pain remains a major health care problem posing numerous challenges for researchers,
practitioners, policy makers and patients alike. In this review, I have used a broad lens to explore a
variety of contemporary matters associated with chronic pain. I have argued that pain is perplexing,
subjective and amorphous and some patients feel that health care providers do not believe that they
have significant pain. I have argued that it is not possible to disprove a person’s pain and that the
association between pain and pathology may be tenuous in some circumstances. I described the
consequences of long-term prescribing of analgesic medication and offered examples of service delivery
that may promote a biopsychosocial model of care at the first point of contact in primary care.
Ultimately, pain is a psychological construct arising from physiological processes occurring in
the brain. I have described pain as a top-down perceptual inference that integrates sensory, motor,
affective, cognitive, social and environmental contexts to update the final experience of pain. I argue
that pain does not faithfully reflect tissue status but serves instead to infer bodily threat and drive
behaviors to reduce the impact of threat on the integrity of the body. I have provided examples of
the malleability of pain perception and offered examples of interventions that manipulate context to
alleviate pain. Finally, I have speculated that modern urban environments are painogenic in nature and
incompatible with Paleolithic physiology encoded by our genetic heritage. I believe that exploration
of pain through the lens of evolutionary mismatch may provide novel insights to why patients have
difficulties adhering to healthy lifestyles and provide upstream strategies to reduce the burden of
chronic pain on society.
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